Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev said India plans to produce around 300 million doses of the Russian Sputnik V Covid-19 vaccine next year.
“In India, we have agreements with four major manufacturers. … India will produce around 300 million doses or more of the vaccine for us next year,” said Kirill Dmitriev. Tass News Agency in an interview, adding that production was due to start in early 2021.
Read also | Covid curve collapsing across India
RDIF’s CEO further added that out of 110 manufacturing sites that have negotiated the production of the Russian coronavirus vaccine, RDIF has chosen 10 that meet its requirements.
“Russian Sputnik V will be actively produced around the world and we see that it is built on a secure platform based on human adenovirus,” Dmitriev added.
The Russian Embassy in India sued the CEO of RDIF and said today that the country is testing the first samples of its Sputnik V vaccine that we have produced in India.
Russian Sputnik V is 95% effective
A few days ago, Russia said interim results from Sputnik V clinical trials showed the Covid-19 vaccine was 95% effective, similar to other international vaccine manufacturers who also published test results showing efficacy rates. 90% and higher.
The Russian Ministry of Foreign Affairs (MAE) quoted President Vladimir Putin on Twitter and said some health specialists said the vaccine’s protection level is as high as 96-97%.
“Putin: Russia was the first country in the world to have invented and started producing the COVID19 vaccine. And we have a good vaccine, safe and efficient – over 95% – and specialists say its protection level reaches 96-97%, “MFA Russia tweeted.
Putin said last Thursday that he still needed to be vaccinated with Sputnik V, but that he would do so whenever possible.
Russia launched the Sputnik V jab at doctors and other frontline workers in Moscow this month, and over 200,000 people have already been vaccinated in the country.
Meanwhile, Russia has also said that the Sputnik V vaccine will be priced at $ 10 per dose in international markets, a lower cost than other registered coronavirus vaccines.